RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
  NHS
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
UK Channel

subscribe to UK newsletter
Healthcare : UK

   EMAIL   |   PRINT
NICE issues draft guidance on Trastuzumab

Jun 10, 2006 - 5:15:00 PM , Reviewed by: Priya Saxena
“These proposals are very good news for women with HER2 positive breast cancer. Herceptin, for these women is clinically and cost effective in the early stage of the disease and we look forward to being able to issue final guidance, subject to any appeal against our recommendations, in a few weeks time.”

 
[RxPG] NICE has published draft guidance on Herceptin, just two weeks after the drug was licensed by the regulatory authorities for use in early breast cancer. The draft guidance recommends the drug for women with early stage HER2-positive breast cancer, except where there are concerns about the woman’s cardiac function. Final guidance is expected to be issued at the beginning of July 2006, assuming there are no appeals.

NICE Chief Executive Andrew Dillon said: “These proposals are very good news for women with HER2 positive breast cancer. Herceptin, for these women is clinically and cost effective in the early stage of the disease and we look forward to being able to issue final guidance, subject to any appeal against our recommendations, in a few weeks time.”

The draft recommendations by NICE are:

1.1 Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as a treatment option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).

1.2 Cardiac function should be assessed prior to the commencement of therapy and trastuzumab treatment should not be offered to women who have a left ventricular ejection fraction (LVEF) of 55% or less, or who have any of the following:
• a history of documented congestive heart failure
• high-risk uncontrolled arrhythmias
• angina pectoris requiring medication
• clinically significant valvular disease
• evidence of transmural infarction on electrocardiograph (ECG)
• poorly controlled hypertension.

1.3 Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10% from baseline and to below 50% then trastuzumab treatment should be suspended. A decision to resume trastuzumab therapy should be based on a further cardiac assessment and a fully informed discussion of the risks and benefits between the individual patient and their clinician.

The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. NICE produces guidance in three areas of health: public health guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector; health technologies guidance on the use of new and existing medicines, treatments and procedures within the NHS; and clinical practice guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS. NICE issues guidance on the clinical and cost effectiveness of selected new and existing drugs for the NHS in England and Wales. It does this after new medicines have been licensed by the Medicines and Healthcare products Regulatory Agency/European Medicines Evaluation Agency.



Publication: National Institute for Health and Clinical Excellence (NICE)
On the web: www.nice.org.uk 

Advertise in this space for $10 per month. Contact us today.


Related UK News
Leading OCD expert welcomes Charles Walker MP's honesty
British court orders force-feeding for dying anorexic woman
Systematic bias in the assessment of UK doctors
Why women in UK can't find sperm donors?
Britain reviews child protection after toddler's death by torture
Most British Women Unaware of Lifestyle Stroke Risks
Depression is wrongly seen as natural part of getting older
Drink and drugs fuel Scottish suicide and homicide rates
NRI doctor guilty of unethical tests on British patients
Healthcare commissioning- ?Adverse to patient care

Subscribe to UK Newsletter

Enter your email address:


 Additional information about the news article
NICE has introducing a new, rapid process to enable faster guidance on life-saving drugs which have already been licensed and on new medicines close to when they first become available. Details can be found on the NICE website.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)